Skip to main content
logo
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
3.545
-0.525 (-12.90%)
Sep 23, 2026, 11:49 AM EDT - Market open

Lexeo Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.651.66
Revenue Growth
-----60.53%219.59%
Cost of Revenue
66.6463.874.0953.1349.1645.12
Gross Profit
-66.64-63.8-74.09-53.13-48.51-43.46
Selling, General & Admin
28.4845.4631.6815.38127.17
Operating Expenses
28.4845.4631.6815.38127.17
Operating Income
-95.12-109.26-105.77-68.51-60.51-50.64
Interest Expense
-0.07-0.1-0.14-0.21-0.09-
Interest & Investment Income
7.986.137.562.871.330.02
Other Non Operating Income (Expenses)
-0.01-0.02-0.01-0.54-0-
EBT Excluding Unusual Items
-87.22-103.24-98.36-66.39-59.28-50.62
Gain (Loss) on Sale of Investments
-0.043.280.02---
Pretax Income
-87.27-99.96-98.33-66.39-59.28-50.62
Net Income
-87.27-99.96-98.33-66.39-59.28-50.62
Net Income to Common
-87.27-99.96-98.33-66.39-59.28-50.62
Net Income Growth
------
Shares Outstanding (Basic)
765432522
Shares Outstanding (Diluted)
765432522
Shares Change
113.19%68.76%493.67%228.42%5.00%7.72%
EPS (Basic)
-1.15-1.86-3.09-12.40-36.36-32.60
EPS (Diluted)
-1.15-1.86-3.09-12.40-36.36-32.60
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-88.7-98.96-81.63-59.61-55.23-44.37
Free Cash Flow Per Share
-1.17-1.84-2.57-11.13-33.88-28.58
Operating Margin
-----9252.14%-3055.94%
Profit Margin
-----9063.76%-3055.04%
Free Cash Flow Margin
-----8445.26%-2677.73%
EBITDA
-94.5-108.67-105.14-67.94-60.24-50.62
D&A For EBITDA
0.610.590.630.580.270.01
EBIT
-95.12-109.26-105.77-68.51-60.51-50.64
Revenue as Reported
----0.651.66
SEC Filings: 10-K · 10-Q